Clinical trials: Unspecified Adult Solid Tumor, Protocol Specific, completed
AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin in…
- Conditions
- AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00004241
- Testing
- tanespimycin, pharmacological study
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
E7070 in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of E7070 in treating patients who have solid tumors.
- Trial name
- NCT00003976
- Testing
- indisulam
- Where
- 27 sites in Austria, Belgium and 7 more
- Volunteers
- 30 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Unspecified Adult Solid Tumor, Protocol Specific
Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
Drugs used in chemotherapy, such as irinotecan, oxaliplatin, and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00074321
- Testing
- irinotecan hydrochloride, oxaliplatin, capecitabine
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
SU6668 in Treating Patients With Advanced Solid Tumors
Phase I trial to study the effectiveness of SU6668 in treating patients who have advanced solid tumors. SU6668 may stop the growth of solid tumors by stopping blood flow to the tumor
- Trial name
- NCT00024206
- Testing
- orantinib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A in Treating Patients With Advanced Solid Tumors
RATIONALE: Radiolabeled monoclonal antibodies, such as yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00645060
- Testing
- high performance liquid chromatography, pharmacological study, radionuclide imaging
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Unspecified Adult Solid Tumor, Protocol Specific
Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00541359
- Testing
- bortezomib, topotecan hydrochloride, immunohistochemistry staining method
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- City of Hope Medical Center
Unspecified Adult Solid Tumor, Protocol Specific
Endostatin in Treating Patients With Advanced Solid Tumors
Phase I trial to study the effectiveness of endostatin in treating patients who have advanced solid tumors. Endostatin may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00004229
- Testing
- recombinant human endostatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Anemia, Leukemia
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia caused by cancer and chemotherapy.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00255749
- Testing
- epoetin alfa
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
ILX23-7553 in Treating Patients With Solid Tumors That Have Not Responded to Previous Therapy
RATIONALE: ILX23-7553 may help solid tumor cells develop into normal cells. PURPOSE: Phase I trial to study the effectiveness of ILX23-7553 in treating patients who have solid tumors that have not responded to previous therapy.
- Trial name
- NCT00004926
- Testing
- vitamin D3 analogue ILX23-7553
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
Study of Hair Samples From Patients With Cancer
RATIONALE: Studying samples of hair in the laboratory from patients with cancer may help doctors identify biomarkers related to cancer and predict how well patients will respond to treatment.
- Trial name
- NCT00899691
- Testing
- protein expression analysis
- Volunteers
- 190 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Unspecified Adult Solid Tumor, Protocol Specific
Nutrition Education for Low-Income Healthy Participants Who Eat an Unhealthy Diet
RATIONALE: Decreasing the amount of fat in the diet and increasing fruit and vegetable intake may help prevent some types of cancer.
- Trial name
- NCT00301691
- Testing
- behavioral dietary intervention, educational intervention, preventative dietary intervention
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Brown University
Unspecified Adult Solid Tumor, Protocol Specific
Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Phase I trial to study the effectiveness of combining bortezomib with paclitaxel in treating patients who have advanced or metastatic solid tumors.
- Trial name
- NCT00030368
- Testing
- bortezomib, paclitaxel, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
This phase I/II trial is studying the side effects and best dose of everolimus when given together with sorafenib tosylate and to see how well they work in treating patients with advanced solid tumors and metastatic pancreatic…
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT00981162
- Testing
- sorafenib tosylate, everolimus, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma
- Trial name
- NCT00003269
- Testing
- sargramostim, amifostine trihydrate, cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Scripps Health
Lymphoma, Small Intestine Cancer
CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy
RATIONALE: CC-5013 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have solid tumors and/or lymphoma that did not respond to…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00031941
- Testing
- lenalidomide
- Where
- 2 sites in United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
This phase I clinical trial is studying the side effects and best dose of RO4929097 when given together with capecitabine in treating patients with refractory solid tumors.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma
- Trial name
- NCT01158274
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, capecitabine, laboratory biomarker analysis
- Where
- 2 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
This phase I trial is studying the side effects and best dose of GTI-2040 and gemcitabine in treating patients with metastatic or unresectable solid tumors.
- Trial name
- NCT00078962
- Testing
- GTI-2040, gemcitabine hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
RATIONALE: Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00033241
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Sponsor
- OSI Pharmaceuticals
Unspecified Adult Solid Tumor, Protocol Specific
BMS-214662 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-214662 in treating patients who have advanced solid…
- Trial name
- NCT00004877
- Testing
- BMS-214662
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific
An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function
This is an open-label non-randomized study in subjects with advanced or metastatic solid tumors who are no longer responding to available therapy. HALAVEN will be administered to subjects on Days 1 and 8 of a 21-day cycle.
- Trial name
- NCT01418677
- Testing
- E7389
- Where
- 9 sites in United States
- Volunteers
- 19 people
- Sponsor
- Eisai Inc.